(46) developed a T2-weighted imaging–based model that demonstrated moderate performance in predicting KRAS mutation status in rectal cancer patients, noting that an increased tumor axial-to-longitudinal size ratio correlates with a higher risk of KRAS mutations. This evidence concerns the gene KRAS and neoplasm.